Status:
COMPLETED
Molecular Profile of the Evolution of Inclusion Body Myositis
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Inclusion Body Myositis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of contr...
Detailed Description
Sporadic inclusion body myositis (sIBM) is a myopathy that usually does not become apparent before the age of 50 to 60. The disease is characterized by a progressive weakening of the muscles, includin...
Eligibility Criteria
Inclusion
- Inclusion Criteria (early-stage sIBM patients):
- Patient suffering from sIMB according to the ENMC 2011 criteria: "sIMB defined on histological and clinical features" with, on the inclusion visit day:
- duration of the disease \> 12 months;
- onset of the disease \> 45 years;
- quadriceps weakness ≥ hip flexors and/or fingers flexors weakness \> shoulder abductors;
- CPK ≤ 15 x ULN.
- Patient with available biopsy showing alterations compatible with an inflammatory myopathy (endomysial inflammatory infiltrate, overexpression of HLA class I), but not specific to sIMB, in particular with no associated degenerative and/or mitochondrial pathologies (protein aggregates: amyloid, p62, SMI-31, TDP-43; 15-18nm filaments; ragged red fibers; COX negative fibers).
- Patient whose sIMB diagnosis has been histologically confirmed with a second muscle biopsy showing the typical histological hallmarks (endomysial inflammatory infiltrate, overexpression of HLA class I and an associated degenerative and/or mitochondrial pathology).
- Patient who gave his consent for the use of the biological material from the muscle biopsy at the time of the diagnosis.
- Patient affiliated to a social security regimen.
- Signed and written informed consent.
- Exclusion Criteria (early-stage sIBM patients):
- Patient with a known medical record that could significantly influence the results of the study: auto-immune disease with conjunctive tissue inflammation (overlap myositis, rheumatoid arthritis, lupus, vasculitis, spondylarthritis, scleroderma, psoriatic arthritis), disease causing nerve-damage (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis), auto-immune neuropathy (chronic polyradiculoneuritis and variants (multifocal motor neuropathy with conduction blocks, anti-MAG neuropathy)).
- Presence of the following histological characteristics in the muscle biopsy pointing to degenerative and/or mitochondrial pathologies: protein aggregates (amyloid, p62, SM-31, TDP-43), 15-18nm filaments, ragged red fibers or fibers with decreased COX activity.
- Patient who received one of the following treatments, prior to the first muscle biopsy:
- anti-inflammatory drugs in the past week;
- corticotherapy in the past month;
- immunosuppressive agents in the past 3 months;
- other treatments: chloridin, amiodarone, colchicine, vincristine in the past 6 months.
- Patient under curators or guardianship.
- Pregnant woman.
- Inclusion Criteria (late-stage sIMB patients):
- Patient suffering from sIMB according to the ENMC 2011 criteria: "sIMB defined on histological and clinical features" with, on the inclusion visit day:
- duration of the disease \> 12 months;
- onset of the disease \> 45 years;
- quadriceps weakness ≥ hip flexors and/or fingers flexors weakness \> shoulder abductors;
- CPK ≤ 15 x ULN.
- Patient whose sIMB diagnosis has been histologically confirmed with a muscle biopsy featuring the following characteristics: endomysial inflammatory infiltrate, rimmed vacuoles and protein aggregates (amyloid, p62, SM-31, TDP-43) or presence of 15-18nm filaments.
- Patient who gave his consent for the use of the biological material from the muscle biopsy at the time of the diagnosis.
- Patient affiliated to a social security regimen.
- Signed and written informed consent.
- Non-inclusion criteria (late-stage sIMB patients):
- Patient with a known medical record that could significantly influence the results of the study: auto-immune disease with conjunctive tissue inflammation (overlap myositis, rheumatoid arthritis, lupus, vasculitis, spondylarthritis, scleroderma, psoriatic arthritis), disease causing nerve-damage (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis), auto-immune neuropathy (chronic polyradiculoneuritis and variants (multifocal motor neuropathy with conduction blocks, anti-MAG neuropathy)).
- Patient who received one of the following treatments, prior to the muscle biopsy that confirmed the diagnosis:
- anti-inflammatory drugs in the past week;
- corticotherapy in the past month;
- immunosuppressive agents in the past 3 months;
- other treatments: chloridin, amiodarone, colchicine, vincristine in the past 6 months.
- Patient under curators or guardianship.
- Pregnant woman.
- Inclusion Criteria (control subjects):
- Signed and written informed consent for the use of muscle tissue used collected for the diagnosis of a CPK elevation and/or myopathy and/or myalgias.
- No signs of muscular weakness at the time of the muscle biopsy.
- Age \> 45, correlated to the age of sIMB patients, allowing for the constitution of a homogeneous group compared to sIMB patients.
- Patient affiliated to a social security regimen.
- Signed and written informed consent.
- Non-inclusion criteria (control subjects):
- Subject with a muscle biopsy showing signs of inflammation and/or vacuoles and/or dystrophy.
- Subject with a known medical record that could significantly influence the results of the study: auto-immune disease with conjunctive tissue inflammation (overlap myositis, rheumatoid arthritis, lupus, vasculitis, spondylarthritis, scleroderma, psoriatic arthritis), disease causing nerve-damage (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis), auto-immune neuropathy (chronic polyradiculoneuritis and variants (multifocal motor neuropathy with conduction blocks, anti-MAG neuropathy)).
- Subject with a confirmed sIMB diagnosis.
- Patient who received one of the following treatments, prior to the muscle biopsy that confirmed the diagnosis:
- anti-inflammatory drugs in the past week;
- corticotherapy in the past month;
- immunosuppressive agents in the past 3 months;
- other treatments: chloridin, amiodarone, colchicine, vincristine in the past 6 months.
- Patient under curators or guardianship.
- Pregnant woman.
Exclusion
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 7 2020
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT03299335
Start Date
February 1 2018
End Date
February 7 2020
Last Update
March 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pasteur 2 - Service Système Nerveux Périphérique, Muscle et SLA
Nice, France, 06001